Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-DOTATATE PET/CT in NETs
NCT07119242Phase 3Active, not recruiting
- Start
- Jan 2024
- Primary completion
- Nov 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gallium ga 68 dotatate in neuroendocrine tumors (NETs). Started Jan 2024; status: active, not recruiting.
02
Drugs
gallium ga 68 dotatate
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT07119242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07119242.